A Series B financing round yielded $85 million for Black Diamond Therapeutics, which it plans to use to support up to three of five drug candidates for human clinical trials, to develop drug technology and to establish a new corporate headquarters in Cambridge, Mass. Black Diamond owns technology that can locate oncogenes and reveal how they are activated, which it says will prove helpful in developing complementary drug therapies.
Biotech firm raises $85M to move drug candidates to clinical trials
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.